The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice
- 1 May 2010
- journal article
- research article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 235 (5), 633-641
- https://doi.org/10.1258/ebm.2009.009229
Abstract
Vascular inflammation and monocyte recruitment are initiating events in atherosclerosis that have been suggested to be caused, in part, by iron-mediated oxidative stress and shifts in the intracellular redox environment of vascular cells. Therefore, the objective of this study was to investigate whether the intracellular iron chelator, desferrioxamine (DFO), reduces inflammation and atherosclerosis in experimental mice. Treatment of C57BL/6J mice with DFO (daily intraperitoneal injection of 100 mg/kg body weight for two weeks) strongly inhibited lipopolysaccharide-induced increases of soluble cellular adhesion molecules and monocyte chemoattractant protein-1 (MCP-1) in the serum and activation of the redox-sensitive transcription factors, nuclear factor-κB and activator protein-1, in the aorta. Furthermore, treatment of apolipoprotein E-deficient (apoE−/−) mice with DFO (100 mg/kg, intraperitoneal, daily for 10 weeks) attenuated aortic atherosclerotic lesion development by 26% (P < 0.05). DFO treatment of apoE−/− mice also lowered serum levels of MCP-1 and gene expression of proinflammatory and macrophage markers in the aorta and heart, in parallel with increased protein expression of the transferrin receptor in the heart and liver. In contrast, DFO treatment had no effect on serum cholesterol and triglyceride levels. These data show that DFO inhibits inflammation and atherosclerosis in experimental mice, providing the proof-of-concept for an important role of iron in atherogenesis. Whether eliminating excess iron is a useful adjunct for the prevention or treatment of atherosclerosis in humans remains to be investigated.Keywords
This publication has 50 references indexed in Scilit:
- Iron in arterial plaque: A modifiable risk factor for atherosclerosisBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- Genetic deficiency of NADPH oxidase does not diminish, but rather enhances, LPS-induced acute inflammatory responses in vivoFree Radical Biology & Medicine, 2008
- Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in miceCardiovascular Research, 2008
- Apolipoprotein C-I Is Crucially Involved in Lipopolysaccharide-Induced Atherosclerosis Development in Apolipoprotein E–Knockout MiceCirculation, 2007
- Reduction of Iron Stores and Cardiovascular Outcomes in Patients With Peripheral Arterial DiseaseJAMA, 2007
- Iron Chelation Inhibits NF-κB–Mediated Adhesion Molecule Expression by Inhibiting p22 phox Protein Expression and NADPH Oxidase ActivityArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Intracellular Labile Iron Modulates Adhesion of Human Monocytes to Human Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Redox Regulation of NF-kappa B ActivationFree Radical Biology & Medicine, 1997
- Iron Overload Augments the Development of Atherosclerotic Lesions in RabbitsArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Role of iron in Trypanosoma cruzi infection of mice.JCI Insight, 1984